The latest price target for Arcturus Therapeutics (NASDAQ:ARCT) was reported by Citigroup on November 13, 2025. The analyst firm set a price target for $9.00 expecting ARCT to rise to within 12 months ...

Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with cystic fibrosis—an outcome William Blair found “potentially promising.” ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market open, ...

After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants exhibited encouraging reduction of mucus plug number and mucus volume 12-week study enrolling up to 20 CF ...

Arcturus stock sinks 56% after cystic fibrosis drug shows no clear lung function gains. Phase 2 data finds ARCT-032 safe but lacking strong efficacy signals so far. Company plans higher-dose, 12-week ...

Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...

Arcturus Therapeutics is transitioning from COVID-era revenues to milestone-driven growth, led by its mRNA platform and strategic partnerships. KOSTAIVE, ARCT's self-amplifying mRNA COVID-19 vaccine, ...

Arcturus Therapeutics (ARCT) shares soared 8.7% in the last trading session to close at $19.62. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Shannon Silverman, an Astrophysicist at the Clay Center in Charleston West Virginia, guides us through the cosmos above West Virginia. In this episode she tells us about some of the summer's brightest ...